证券代码：000766 证券简称：通化金马 公告编号：2025-25 通化金马药业集团股份有限公司 第十一届董事会2025年第六次临时会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、通化金马药业集团股份有限公司第十一届董事会2025年第六次临时会议 通知于2025年5月29日以微信、电子邮件形式送达全体董事。 2、2025年5月30日上午9时30分在公司七楼会议室以现场和通讯方式召开。 3、会议应到董事9人，实到董事9人。 4、会议由董事长张玉富先生主持。监事会成员及部分高管人员列席了本次 会议。 5、本次董事会会议的召开符合有关法律、行政法规、部门规章、规范性文 件和公司章程的规定。 二、董事会会议审议情况 1、审议并通过《关于修改〈公司章程〉的议案》 根据《公司法》《证券法》《上市公司章程指引（2025 年修订）》及中国证 券监督管理委员会发布的《关于新<公司法>配套制度规则实施相关过渡安排》 等相关法律法规、规范性文件的最新规定，结合公司实际，对《公司章程》进 行修改和完善。具体修改内容详见公司同日披露的《关于修 ...

Group 1: Financial Performance and Debt Management - The company aims to gradually reduce its high debt ratio as its operational stability and profitability improve [2] - The company has not distributed dividends for 20 years, and future dividend distribution will depend on legal regulations and company policies [3] Group 2: New Drug Development and Market Potential - The new drug, HuPo BaTian Nian An Dian Pian, is designed to meet the needs of over 300 million elderly patients in China suffering from Alzheimer's disease [2] - The production system is built according to GMP standards, ensuring that it can meet domestic demand for Alzheimer's medication upon approval [4] - The drug has received acceptance for its listing application from the National Medical Products Administration, entering the review phase [3][5] Group 3: Competitive Landscape and Pricing Strategy - The company is aware of competitive products like Lecanemab and Galantamine, and is strategizing on pricing and market entry for its new drug [3] - The company emphasizes that its new drug offers significant patient benefits without increasing safety risks compared to existing treatments [8] Group 4: Intellectual Property and Regulatory Compliance - The new drug has received patent protection in multiple countries, including Japan and 15 European nations, with a U.S. patent expected by September 2024 [4] - The review process for the new drug is proceeding normally, and the company is committed to timely disclosures regarding its progress [6][7] Group 5: Future Outlook and Strategic Plans - The company plans to enhance its innovation capabilities and adjust its product structure to improve revenue growth [7] - The new drug is expected to significantly enhance the company's profitability once it is commercialized [8]

为进一步加强与投资者的互动交流，通化金马药业集团股份有限公司（以下 简称"公司"）将参加由吉林省证券业协会、深圳市全景网络有限公司共同举办 的"2025 年吉林辖区上市公司投资者网上集体接待日活动"，现将有关事项公告 如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景路 演 APP,参与本次互动交流。活动时间为 2025 年 5 月 27 日（周二）15:00-16:30。 届时公司董事长、总经理张玉富先生，财务负责人、副总经理于军先生，独 立董事吕桂霞女士，董事会秘书贾伟林先生将通过网络在线问答互动的形式，就 公司 2024 年度业绩、公司治理、发展战略、经营状况等投资者关心的问题，与 投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 关于参加 2025 年吉林辖区上市公司投资者 证券代码：000766 证券简称：通化金马 公告编号：2025-24 网上集体接待日活动的公告 通化金马药业集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 通 ...

Summary of Key Points Core Viewpoint - As of May 16, the total market financing balance decreased to 1.79 trillion yuan, indicating a slight reduction in investor activity in the market [1]. Company and Industry Analysis - The financing balance in the Shanghai market was 907.43 billion yuan, down by 0.92 billion yuan, while the Shenzhen market's balance was 882.06 billion yuan, also down by 0.92 billion yuan. The North Exchange's financing balance decreased to 5.38 billion yuan, down by 0.038 billion yuan [1]. - On May 16, a total of 1,712 stocks received net financing purchases, with 257 stocks having net purchases exceeding 10 million yuan. Notably, 22 stocks had net purchases over 50 million yuan [1]. - The top three stocks by net financing purchases on May 16 were: - China Merchants Bank: 170.42 million yuan - Tonghua Golden Horse: 167.08 million yuan - China Ping An: 136.61 million yuan [2]. - The industries with the highest concentration of stocks receiving net financing purchases over 50 million yuan included automotive, basic chemicals, and food and beverage, each with three stocks listed [1]. - The average ratio of financing balance to circulating market value for stocks with significant net purchases was 4.01%, with Dongtu Technology having the highest ratio at 9.79% [2]. - The financing net purchase rankings on May 16 highlighted several stocks, including: - Dongtu Technology: 8.04 million yuan, 7.58% increase - Tonghua Golden Horse: 16.71 million yuan, 2.45% increase - BYD: 9.85 million yuan, 3.28% increase [2][3].

Summary of Key Points Core Viewpoint - As of May 6, the total market financing balance reached 1.79 trillion yuan, indicating an increase of 143.81 billion yuan from the previous trading day, with notable contributions from both the Shanghai and Shenzhen stock exchanges [1]. Financing Balances - Shanghai stock exchange financing balance: 908.24 billion yuan, up by 59.40 billion yuan - Shenzhen stock exchange financing balance: 876.71 billion yuan, up by 83.55 billion yuan - Beijing Stock Exchange financing balance: 5.12 billion yuan, up by 86.21 million yuan [1]. Individual Stock Performance - On May 6, 2,239 stocks received net financing purchases, with 566 stocks having net purchases exceeding 10 million yuan, and 21 stocks exceeding 100 million yuan [1]. - Leading net purchases included: - Luxshare Precision: 228 million yuan - Runhe Software: 212 million yuan - Changshan Beiming: 199 million yuan - Other notable stocks: Inspur Information, Sichuan Changhong, and Dongfang Caifu [1][2]. Industry Concentration - The industries with the highest concentration of stocks receiving net financing purchases over 100 million yuan included: - Computer: 5 stocks - Non-ferrous metals: 3 stocks - Electronics: 3 stocks [1]. Financing Balance to Market Value Ratio - The average ratio of financing balance to circulating market value for stocks with significant net purchases was 4.78% - Stocks with the highest ratios included: - Hanyu Group: 9.63% - Guanghetong: 8.53% - Dongfang Caifu: 7.51% - Runhe Software: 7.49% [2][3]. Notable Stock Data - Top net purchases on May 6 included: - Luxshare Precision: 3.11% increase, net purchase of 227.62 million yuan - Runhe Software: 9.55% increase, net purchase of 212.02 million yuan - Changshan Beiming: 10.02% increase, net purchase of 198.69 million yuan - Other significant stocks included Inspur Information, Sichuan Changhong, and Dongfang Caifu [2][3].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000766 证券简称：通化金马 公告编号：2025-23 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第一季度报告是否经审计 □是 √否 一、主要财务数据 单位：元 ■ 其他符合非经常性损益定义的损益项目的具体情况 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 √否 ■ （二） 非经常性损益项目和金额 √适用 □不适用 ■ 二、股东信息 （一） 普通股股东总数和表决权恢复的优先股股东数量及前十名股东持股情况表 ■ □适用 √不适用 公司不存在其他符合非经常性损益定义的损益项目的具体情况。 将《公开发行证券的公司信息披露解释性公告第1号一一非经常性损益》中列举的非经常性损益项目界 定为 ...

前十大流通股东累计持有： 38297.27万股，累计占流通股比： 39.65%，较上期变化： 678.91万股。 | 名称 | 持有数量(万股) | 占总股本比 | 增减情况 | | --- | --- | --- | --- | | | | 例(%) | (万股) | | 于兰军 | 19000.00 | 19.67 | 不变 | | 李佳 | 4099.99 | 4.24 | 不变 | | 孙常好 | 3899.99 | 4.04 | 不变 | | 上海木恺贸易有限公司 | 2865.20 | 2.97 | 386.20 | | 唐骁妮 | 2000.00 | 2.07 | 不变 | | 通化市永信投资有限责任公司 | 2000.00 | 2.07 | 不变 | | 田建峰 | 1768.00 | 1.83 | 259.58 | | 上海银行（601229）股份有限公司-银华中证创新药产业交 | | | | | 易型开放式指数证券投资基金 | 1210.32 | 1.25 | 新进 | | 大连喜来商贸有限公司 | 730.00 | 0.76 | 不变 | | 招商银行股份有限公司-南方中证1000交易型 ...

证券代码：000766 证券简称：通化金马 公告编号：2025-22 通化金马药业集团股份有限公司 第十一届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 会议以 3 票赞同，0 票反对，0 票弃权，审议通过了公司 2025 年第一季度报 告。 三、备查文件 2. 2025 年 4 月 18 日上午 11 时以现场和通讯方式召开。 3.会议应到监事 3 人，实到监事 3 人。 4.会议由监事会主席许长有主持。 5.本次监事会会议的召开符合有关法律、行政法规、部门规章、规范性文件 和公司章程的规定。 二、监事会会议审议情况 审议公司 2025 年第一季度报告 监事会的专项审核意见：经审核，监事会认为董事会编制和审议公司 2025 年第一季度报告的程序符合法律、行政法规及中国证监会的规定，报告内容真实、 准确、完整地反映了上市公司的实际情况，不存在任何虚假记载、误导性陈述或 者重大遗漏。 公司 2025 年第一季度报告同日披露于巨潮资讯网。 1.通化金马药业集团股份有限公司第十一届监事会第九次会议通知于 2025 ...

通化金马药业集团股份有限公司 第十一届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1.通化金马药业集团股份有限公司第十一届董事会第九次会议通知于 2025 年 4 月 8 日以微信和电子邮件形式送达全体董事。 2. 2025 年 4 月 18 日上午 9 时 30 分以现场和通讯方式召开。 3.会议应到董事 9 人，实到董事 9 人。 证券代码：000766 证券简称：通化金马 公告编号：2025-21 5.本次董事会会议的召开符合有关法律、行政法规、部门规章、规范性文件 和公司章程的规定。 二、董事会会议审议情况 审议公司 2025 年第一季度报告 公司 2025 年第一季度报告同日披露于巨潮资讯网。 本议案已经董事会审计委员会全票审议通过。 会议以 9 票赞同，0 票反对，0 票弃权，审议通过了公司 2025 年第一季度报 告。 三、备查文件 经与会董事签字并加盖董事会印章的董事会决议。 通化金马药业集团股份有限公司董事会 2025 年 4 月 18 日 4.会议由董事长张玉富先生主持。监事会成员及部分 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 299,282,436.73, representing a 1.25% increase compared to CNY 295,573,016.13 in the same period last year[4] - Net profit attributable to shareholders increased by 26.09% to CNY 11,582,762.07 from CNY 9,186,280.68 year-on-year[4] - The basic and diluted earnings per share rose by 26.32% to CNY 0.0120 from CNY 0.0095 in the same quarter last year[4] - The company's net profit for the current period is 11,569,989.81, an increase of 26.2% compared to 9,165,796.92 in the previous period[20] - Operating profit reached 14,335,267.74, up from 10,878,079.74, reflecting a growth of 31.3%[20] - The total profit for the current period is 14,416,192.63, compared to 10,864,139.42 in the previous period, showing an increase of 32.5%[20] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly to CNY 41,800,049.38, a 473.28% increase from a negative CNY 11,198,052.98 in the previous year[4] - Cash and cash equivalents at the end of the period amounted to ¥332,013,374.68, up from ¥274,177,490.80 at the beginning of the period, showing a growth of about 21.0%[14] - Cash and cash equivalents at the end of the period totaled 331,618,632.84, an increase from 240,560,041.23 in the previous period, reflecting a growth of 37.9%[22] Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,523,874,132.66, a 0.90% increase from CNY 4,483,618,602.64 at the end of the previous year[4] - Total current assets rose to ¥1,264,262,686.64 from ¥1,209,964,232.75, indicating an increase of about 4.5%[15] - Total liabilities increased to ¥2,256,901,221.08 from ¥2,228,215,680.87, reflecting a growth of approximately 1.3%[16] - Non-current assets decreased slightly to ¥3,259,611,446.02 from ¥3,273,654,369.89, indicating a decline of approximately 0.43%[15] Research and Development - The company's R&D expenses increased by 36.07% to CNY 10,687,229.31 compared to CNY 7,854,193.40 in the same period last year[8] - Research and development expenses increased to 10,687,229.31, up from 7,854,193.40, representing a rise of 35.5%[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 37,074[10] - The largest shareholder, Yu Lanjun, holds 19.66% of the shares, amounting to 190,000,000 shares, with 150,000,000 shares pledged[11] Other Income and Expenses - The company reported a decrease of 49.60% in other income, totaling CNY 2,026,653.35 compared to CNY 4,021,420.65 in the previous year[8] - The income tax expense increased by 67.59% to CNY 2,846,202.82 from CNY 1,698,342.50 year-on-year[8] - The company incurred financial expenses of 19,607,550.57, up from 15,278,523.05, which is an increase of 28.5%[20] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[24]